Pl@ntNet

Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

Retrieved on: 
Thursday, December 22, 2022

“An approach that can directly target the tumor microenvironment with an immunomodulatory ADC has the potential to bring the benefits of this immunotherapy to a broader group of patients.

Key Points: 
  • “An approach that can directly target the tumor microenvironment with an immunomodulatory ADC has the potential to bring the benefits of this immunotherapy to a broader group of patients.
  • Mersana has generated preclinical data demonstrating Immunosynthen’s ability to enable highly targeted STING activation within both tumor cells and tumor-resident myeloid cells while avoiding unwanted systemic effects.
  • “We are pleased to be partnering with Merck KGaA, Darmstadt, Germany in a collaboration designed to extend the reach of our Immunosynthen platform and bring novel new product candidates forward with the potential to benefit patients,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics.
  • Mersana will be responsible for certain discovery activities, as well as limited preclinical manufacturing and supply obligations, which will be reimbursed by Merck KGaA, Darmstadt, Germany.

Increase of 40% in the Trading Volumes of the Dual-Listed Shares on The Tel Aviv Stock Exchange (TASE)

Retrieved on: 
Wednesday, June 1, 2022

TEL AVIV, Israel, June 1, 2022 /PRNewswire/ -- According to Yuval Tsuk, Research Unit at the Tel Aviv Stock Exchange (TASE: TASE), The dual-listed companies, which are simultaneously traded on TASE and on international exchanges, have a material effect on the Israeli equity market, in general, and on the flagship indices, in particular. 50 dual-listed companies are currently traded on TASE, most of which are simultaneously traded in the United States.

Key Points: 
  • The TA-125 Index includes 21 dual shares, which accounted for 33% of the weight of the index, and the trading in which represented 27% of the total trading in all shares of the index.
  • The trading volume of the dual-listed shares accounted for 25% of the total average trading volume of shares on TASE.
  • For most dual-listed shares that experienced a rise in trading volumes in the first quarter of 2022 compared to 2021, the trading volume on TASE rose more sharply than the trading volume abroad.
  • However, for most dual-listed shares that experienced a downturn in trading volumes in the first quarter of 2022, the reduction in the trading volume was more moderate on TASE.

Fujitsu and RIKEN start joint research on next-generation IT drug discovery technology using the supercomputer Fugaku and simulation integrated AI

Retrieved on: 
Tuesday, May 17, 2022

The joint research project will leverage high performance computing technologies and the supercomputer Fugaku to accelerate simulation integrated AI that combines Fujitsu's DeepTwin AI technology, which accurately acquires quantitative features from complex data by unsupervised learning, with molecular dynamics simulation using RIKEN's AI drug discovery simulation technology.

Key Points: 
  • The joint research project will leverage high performance computing technologies and the supercomputer Fugaku to accelerate simulation integrated AI that combines Fujitsu's DeepTwin AI technology, which accurately acquires quantitative features from complex data by unsupervised learning, with molecular dynamics simulation using RIKEN's AI drug discovery simulation technology.
  • Based on this research, the two parties aim to develop a next-generation IT drug discovery technology with world-leading capabilities by the end of fiscal 2026.
  • RIKEN and Fujitsu will work together to transform the drug discovery process by truly integrating computing technologies such as the supercomputer Fugaku with leading edge AI and machine learning technologies.
  • In this joint research project, Fujitsu and RIKEN will collaborate to develop the world's best computational technology for drug discovery using the world-class supercomputer Fugaku.

Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology

Retrieved on: 
Thursday, December 9, 2021

We are honored to welcome Dr. Tabernero and Dr. Venook to our scientific advisory board, commented Masoud Tavazoie, M.D., Ph.D., Chief Executive Officer of Inspirna.

Key Points: 
  • We are honored to welcome Dr. Tabernero and Dr. Venook to our scientific advisory board, commented Masoud Tavazoie, M.D., Ph.D., Chief Executive Officer of Inspirna.
  • Both individuals are experts in their respective fields and have extensive clinical experience in Gastrointestinal oncology and the development of molecular targeted therapies.
  • I am pleased to be joining the Scientific Advisory Board at Inspirna, said Dr. Tabernero.
  • The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers.